Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Up 8.0% in March

Delcath Systems, Inc. (NASDAQ:DCTH) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 898,900 shares, an increase of 8.0% from the February 29th total of 832,700 shares. Based on an average daily volume of 235,400 shares, the days-to-cover ratio is presently 3.8 days.

Insider Activity

In related news, Director Gil Aharon purchased 26,882 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were acquired at an average cost of $3.72 per share, for a total transaction of $100,001.04. Following the acquisition, the director now owns 1,069,710 shares of the company’s stock, valued at approximately $3,979,321.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 21.10% of the company’s stock.

Institutional Trading of Delcath Systems

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Delcath Systems by 19.7% in the fourth quarter. Vanguard Group Inc. now owns 522,008 shares of the company’s stock worth $2,172,000 after buying an additional 85,948 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Delcath Systems in the fourth quarter worth about $962,000. Northern Trust Corp grew its position in shares of Delcath Systems by 82.7% during the 4th quarter. Northern Trust Corp now owns 60,667 shares of the company’s stock valued at $252,000 after acquiring an additional 27,458 shares during the period. AIGH Capital Management LLC purchased a new position in shares of Delcath Systems in the 4th quarter valued at about $4,918,000. Finally, Worth Venture Partners LLC acquired a new position in Delcath Systems in the 4th quarter worth about $1,224,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Analyst Ratings Changes

DCTH has been the topic of several recent analyst reports. HC Wainwright upped their target price on Delcath Systems from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, March 27th. StockNews.com raised shares of Delcath Systems to a “sell” rating in a research report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $18.50.

Delcath Systems Stock Performance

Shares of DCTH opened at $4.87 on Thursday. The stock has a 50-day moving average of $4.40 and a two-hundred day moving average of $3.85. The stock has a market cap of $119.61 million, a P/E ratio of -1.64 and a beta of 0.53. Delcath Systems has a one year low of $2.25 and a one year high of $7.99.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Tuesday, March 26th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.19. Delcath Systems had a negative return on equity of 563.60% and a negative net margin of 2,308.86%. The firm had revenue of $0.54 million during the quarter, compared to the consensus estimate of $0.48 million. During the same quarter in the previous year, the company posted ($0.86) earnings per share. Analysts predict that Delcath Systems will post -1.45 EPS for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.